Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Colorcon
Merck
Medtronic
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIPYRIDAMOLE

See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Dipyridamole

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02273518 Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers Completed Boehringer Ingelheim Phase 1 2001-04-01 Comparative pharmacokinetics of dipyridamole in two new formulations of Asasantin ER compared to the present commercial formulation
New Formulation NCT02273531 Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers Completed Boehringer Ingelheim Phase 1 2004-01-01 Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®)
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Dipyridamole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000463 Post Coronary Artery Bypass Graft (CABG) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1987-04-01 To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000496 Platelet Drug Trial in Coronary Disease Progression Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1979-12-01 To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in reducing the angiographic progression of coronary artery disease over a five-year period and to test the predictive value of the platelet survival half-life in identifying patients with more rapid progression of coronary disease and development of its complications.
NCT00000510 Platelet-Inhibitor Drug Trial in Coronary Angioplasty Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1983-09-01 To determine the effectiveness of dipyridamole and aspirin in prevention of restenosis of the dilated lesion in patients who had undergone percutaneous transluminal coronary angioplasty (PTCA). Secondary aims were to determine the effectiveness of platelet inhibitor therapy in reducing the incidence of coronary events and the severity and incidence of angina.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dipyridamole

Condition Name

Condition Name for Dipyridamole
Intervention Trials
Healthy 12
Stroke 4
Heart Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dipyridamole
Intervention Trials
Coronary Artery Disease 11
Myocardial Ischemia 11
Ischemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dipyridamole

Trials by Country

Trials by Country for Dipyridamole
Location Trials
United States 120
Canada 14
Netherlands 12
Italy 6
China 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dipyridamole
Location Trials
Ohio 6
Oklahoma 5
Arizona 5
Texas 4
Kentucky 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dipyridamole

Clinical Trial Phase

Clinical Trial Phase for Dipyridamole
Clinical Trial Phase Trials
Phase 4 19
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dipyridamole
Clinical Trial Phase Trials
Completed 43
Recruiting 8
Unknown status 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dipyridamole

Sponsor Name

Sponsor Name for Dipyridamole
Sponsor Trials
Boehringer Ingelheim 18
Radboud University 10
National Heart, Lung, and Blood Institute (NHLBI) 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dipyridamole
Sponsor Trials
Other 54
Industry 31
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
Harvard Business School
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.